Showing 1–12 of 37 results
Systemic therapy of advanced hepatocellular carcinoma (HCC) with the small molecule multi-kinase inhibitor sorafenib is associated with large inter-individual pharmacokinetic…
Read MoreSmall ubiquitin-like modifier (SUMO) is a member of a ubiquitin-like protein superfamily. SUMOylation is a reversible posttranslational modification that has…
Read MoreSeveral Bevacizumab products are approved for clinical use, with many others in late-stage clinical development worldwide. To aid the harmonization…
Read MoreDenosumab (Prolia®) is a fully human sequence derived monoclonal antibody used for the treatment of osteoporosis in menopausal women via…
Read MoreKinase targets have been extensively studied in biochemical assays using purified protein fragments for the kinase and the substrate. However,…
Read MoreCheckpoint blockade antibodies are established cancer therapeutics. However, in recent years, agonistic antibodies have emerged as therapeutics not only for…
Read MoreBiological activity of a biotherapeutic is a Critical Quality Attribute (CQA), which needs to be accurately measured by an appropriate…
Read MoreDrugs interact with living physiology; an in vitro assay of drug activity can be considered a snapshot of the full…
Read MoreSHP2 (Src-homology 2 domain-containing phosphatase 2) is a protein tyrosine phosphatase encoded by the human PTPN11 gene.SHP2 is a key…
Read MoreHistone modifications are essential in eukaryotic gene expression and regulation, and are driven by histone writer, eraser, and reader proteins.…
Read MoreImmune checkpoint receptors play a key role in maintaining antitumor immunity, avert immunopathology, and modulate overall immune homeostasis. However, cancer…
Read MoreGPCRs are privileged drug targets. Approximately 100 receptors still escape from the drug discovery process as they are orphans, without…
Watch Now
